COMMUNIQUÉS West-GlobeNewswire

-
Nylon flexTAP®: First FDA cleared 3D-Printed Midline Oral Appliance for Sleep Apnea
17/09/2025 -
Synergy CHC Corp. (NASDAQ: SNYR) Partners with AlaBev to Launch FOCUSfactor® Beverages in 5,000+ Retail Outlets Across Alabama
17/09/2025 -
24/7 Market News: Kraig Labs Spider Silk is Sustainable Alternative to Petroleum-Derived Plastics
17/09/2025 -
New Study Highlights the Potential of Hyperbaric Oxygen Therapy as a Biologically Based Treatment for Long-Term PTSD Symptom Improvement
17/09/2025 -
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
17/09/2025 -
Acentra Health Named one of the ‘Fastest Growing Companies’ by the Washington Business Journal
17/09/2025 -
Notice of Annual General Meeting 2025
17/09/2025 -
Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection
17/09/2025 -
Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial Results
17/09/2025 -
MyCardiologist Launches Immediate Care Clinic, Offering Same-Day Access to Expert Cardiac Care
17/09/2025 -
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
17/09/2025 -
Amphista Therapeutics discloses first details of its SMARCA2 degrader program
17/09/2025 -
AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
17/09/2025 -
Pneumagen Launches NeumoBind™ Technology Platform to Unlock New Opportunities in Intranasal Therapeutics
17/09/2025 -
TRUE-See Announces Strategic Partnership with Dr. Peter Chang and the Center for Applied AI Research at the University of California, Irvine
17/09/2025 -
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
17/09/2025 -
Broken Coast Cannabis Brand Launches Premium and Limited BC Selects Line and Unveils New Strain “Sprits 26”, Elevates Craft Portfolio with Modern Blue Dream Release
17/09/2025 -
Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis
17/09/2025 -
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
17/09/2025
Pages